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Although IFN-a, -,B, and -y differ in cell origin, inducing agents, molecular
structure, and cell surface receptors, they share a number ofproperties, including
the induction of antiviral and antiproliferative states and the ability to stimulate
macrophages to develop tumoricidal activity and to downregulate manno-
syl/fucosyl receptors (1, 2) . Simultaneous exposure of fibroblasts, tumor cells, or
macrophages to IFN-y on the one hand, and IFN-a or -a on the other hand,
frequently has a synergistic effect on antiviral and antiproliferative activity (3, 4)
and induction of Fc receptors (5) . However, with the neuroblastoma cell line
T98G, IFN-y antagonizes IFN-a-stimulated antiviral and antiproliferative activ-
ities (6) . Conversely, with macrophages, IFN-aand/or -,# interfere with regulation
by IFN-yofthe expression of la antigens and mannosyl/fucosyl receptors, release
of H202 , and killing of tumor cells (7-11) . The mechanisms underlying these
inhibitory interactions are unknown .
In a survey of cytokines, IFN-y was far more effective than IFN-a or -,Q for
activation ofhuman macrophage oxidative metabolism and antiprotozoal activity
(12) . Study of the latter IFNs was complicated by their apparent toxicity, as
evidenced by sphering of the macrophages and decreased adherence to glass
(12) . Modifications in our method of cell preparation (13) designed to reduce
platelet contamination have now permitted us to establish more robust macro-
phage monolayers . These cultures retain a higher proportion of adherent cells
over 1-2 wk and resist the toxic effects of IFN-a and -,Q . Thus, we wished to
reinvestigate the effects of the IFNs, alone and in combination, on macrophage
H202 secretory capacityand antiprotozoal activity . Two novel findings emerged
(14) : on the one hand, activation of macrophages, but not monocytes, by fairly
high concentrations ofIFN-a and -,B ; and on the other hand, antagonism ofIFN-
y's macrophage-activating effects by far lower concentrations of IFN-a or -f3 .
Examination of the latter interaction at the receptor level led to two further
observations. While monocytes and early macrophages displayed one class of
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IFN-y-R (15-17), the IFN-y-R on mature macrophages appeared to diverge into
two classes of differing affinity. Moreover, IFN-a or -,B seemed selectively and
competitively to blockade the high-affinity IFN-y-R. Differentiation of the hu-
man monocyte in vitro thus appears to be accompanied by complex changes in
binding and signaling characteristics of receptors for each of the IFNs.
Materials and Methods
Interferons. Purified human rIFN--y was generously provided by Genentech, Inc.
(South San Francisco, CA). The specific activity was 3.4 X 10' U/mg protein, as assayed
by inhibition of encephalomyelocarditis virus replication in human lung carcinoma A549
cells in comparison to the National Institutes of Health IFN-y standard. Natural (n)' IFN-
a, affinity purified with an mAb (18), was kindly donated by Dr. M. Wiebe of the New
York Blood Center. The specific activity was 2 X 108 U/mg protein. Purified rIFN-aA,
rIFN-aD, and rIFN-# (sp act 2 X 108 U/mg protein) were generous gifts from Drs. P.
Trown, M. Brunda, and M. Sherman, Hoffman-La Roche, Inc., Nutley, NJ.
Antibodies.
￿
Sheep anti-human IFN-a IgG was purchased from Miles Laboratories Inc.,
Naperville, IL. 1 ml of this antibody neutralized 50,000 U of nIFN-a, as assayed by
induction of H202-releasing capacity. Anti-rIFN-,6, rabbit serum was kindly provided by
Dr. L. S. Lin of Cetus Corp., Emeryville, CA. The neutralization titer was 10,000 U/ml.
Test media were preincubated with antibodies for 30-40 min at room temperature before
use.
Culture of Monocytes.
￿
Healthy adult volunteers of both sexes were phlebotomized
at the New York Blood Center. 450 ml of blood was collected with citrate/dextrose/phos-
phate/adenine (CDPA-1) as an anticoagulant. The buffy coat was obtained 2-3 h after
venipuncture and mononuclear leukocytes (MNLs) were isolated by Ficoll-Hypaque (p =
1 .070; Pharmacia Fine Chemicals, Piscataway, NJ) gradient centrifugation as described
previously (13, 19) with some modifications. Buffy coat (^-20 ml/tube) was centrifuged
three times (500 g for 15, 10, and 10 min at VC, C, respectively) with 40 ml of cold PBS
containing 5.5 mM glucose (PDG). After Ficoll-Hypaque gradient centrifugation at 1,050
g for 25 min at 25 °C, the upper cell layer was suspended in 40 ml of cold PDG, and the
suspension was thoroughly mixed in a 10-ml plastic pipette. After centrifugation at 200 g
for 10 min at 4°C, the cell pellet was washed with cold PDG. After two further
centrifugations (150 g for 10 min at VC), C), the final pellet was suspended in culture
medium, consisting of RPMI 1640 containing 2 mM fresh glutamine (KC Biological, Inc.,
Lenexa, KS), 25% freshly frozen type A human serum prepared as described (13), 100
U/ml penicillin, and 100 ug/ml streptomycin (complete medium). MNL number was
determined by hemocytometer counting. Cell viability, determined by exclusion of 0.2%
trypan blue, was >95% . For experiments with H202 release and for binding studies with
rIFN-y involving macrophages, 1-2 X 106 MNL containing -20-30% cells with monocyte
morphology were dispensed in 0.08 ml ofculture medium per 13-mm diam glasscoverslip.
For binding experiments using monocytes, 2-3 X 106 MNLs were plated per coverslip.
The coverslips were pretreated for 1 wk with 36% HN03 before they were cleaned in
ethanol as described (13). After incubation for 2 h at 37°C in 5% C02/95% humidified
air, the coverslips were rinsed three times in warm Eagle's MEM and transferred to 16-
mm-diam plastic wells in 24-well trays (Costar, Data Packaging Corp., Cambridge, MA)
in 0.3 ml of culture medium. The day of cell preparation was designated day 0. The
medium was replaced on day 1 and every third day thereafter. Results are presented for
cultures in which the cellsadherent on day 8 represented -60% of the monocytes initially
plated. During the 2-yr course of this study, such cultures were consistently obtained for
periods of up to 7 mo (22 consecutive experiments). However, there were two intervals,
lasting several months, in which <_15% of the monocytes remained adherent by day 8.
Stimulatory effects of IFN-a and -S on macrophage H202-releasing capacity were not
uniformly seen in such cultures; these IFNs appeared instead to be toxic.
'Abbreviations used in this paper:
￿
MNL, mononuclear leukocyte; n, natural; PDG, PBS containing
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H202 Release.
￿
Secretion of H202 in response to 100 ng/ml PMA (Sigma Chemical Co.,
St. Louis, MO) was measured in triplicate coverslips by the fluorescent scopoletin assay as
described (13) except that the total volume of reaction mixture was reduced to 0.3 ml
and the same coverslips were used for HQOQ and protein assays without removing the
H202 assay solution. Coverslips were washed thoroughly by swirling in four successive
beakers (200 ml each) of 0.9% NaCl at room temperature, drained on absorbent paper,
and placed in 16-mm-diam wells containing 0.3 ml of Krebs-Ringer PBS with 5.5 mM
glucose, from 5 to 35 nmol scopoletin, 0.3 purpurogallin unit of horseradish peroxidase,
and 30 ng PMA in the presence (0-5 d after MNL preparation) or absence (6 d or later)
of 1 mM NaN, to inhibit myeloperoxidase (13). As controls, cell-free coverslips exposed
to complete medium were rinsed in the same manner and carried through the assay. The
Costar trays were placed in a 37°C water bath for 60 min, the supernatant fluids
transferred to a small glass culture tube (6 x 50 mm; Kimble Div., Owens-Illinois, Inc.,
Toledo, OH), and residual scopoletin fluorescence determined in a Perkin-Elmer-Hitachi
MPF-4A or Spex Fluorolog F112A fluorometer at room temperature. The supernatant
fluids were returned to the original wells and 30 ul of 1 N NaOH added to each well.
After incubation for 30 min at 37°C, protein was measured by the method of Lowry et
al. (20). Specific release (nmol H202/Mg cell protein per 60 min) was calculated by
microcomputer, with corrections for the protein content and fluorescence changes in the
cell-free wells, as described (21).
Antitoxoplasma Activity.
￿
1,000,000 RH strain Tozoplasma gondii trophozoites obtained
from infected mouse peritoneal exudates (22) were added to each 35-mm dish for 30 min.
Uningested organisms were removed by washing (time 0) and coverslips were then
cultured in complete medium. At time 0 and at 20 h after infection, replicate coverslips
were fixed, stained, and scored microscopically for number of toxoplasmas per vacuole
and per 100 macrophages (22).
Radioiodination of rIFN-y.
￿
rIFN-y was labeled with 12'1 as described (23) with modifi-
cations. The pH of rIFN-y solution (25 ,ul, 1 mg/ml) was adjusted to 7.4 with i wl of 0.5
M potassium phosphate buffer, pH 7.4. The solution was mixed with 2 mCi of Na1211 (17
Ci/mmol, carrier-free; Amersham/Searle, Oakville, Ontario), transferred to an Iodogen
(Pierce Chemical Co., Rockford, IL) -coated tube on ice, and mixed gently every 10 s.
After 5 min at 4°C, the reaction was terminated by the addition of 20 ul of 1 M KI. The
reaction mixture was layered on a Sephadex G25 (fine) column (0.9 x 16 cm) in PBS
containing 1 % BSA, and 's1I-rIFN-y was separated from free iodide. After chromatog-
raphy and pooling ofpeak fractions (usually fraction 8-10, 250,ul/fraction), ^-88% of the
original protein was recovered. H202 release assay of all column fractions indicated there
was no inactivation of rIFN-y during the iodination. For nine 12'I-rIFN-y preparations,
specific activity ranged from 0.4-5.1 x 10' cpm/,ug protein (mean t SE = [2.2 t 0.5] x
10' cpm/,ug of protein). Approximately 10 molecules of I- were incorporated per mon-
omer of rIFN-y (the rIFN-y monomer contains four tyrosine residues). Iodinated rIFN-
y was stored at 4°C and couldbe used for at least 3 wk without significant loss of binding
activity.
Assayfor Binding of "'I-rIFN-y to Macrophages.
￿
All binding assays were performed
using cellson glass coverslips in 24-well plastic plates at 4°C. Before assay, culture medium
was replaced by binding buffer, consisting of RPM1 1640 medium, 100 U/ml penicillin,
100 ug/ml streptomycin, 10 mg/ml of BSA, and 50 mM Hepes, pH 7.2. Cells were
incubated with or without competing ligand for 30 min at 4°C. Iodinated rIFN-y was
then added and incubation continued for 2 h at VC. C. Binding was maximal within this
time. Coverslips were then washed in four successive beakers (200 ml each) of 0.9% NaCl
at room temperature, drained on absorbent paper, and placed in the wells of a new 24-
well tray containing 0.5 ml of PBS. The cells were scraped from the coverslips with a
rubber policeman. Duplicate or triplicate suspensions were pooled, carefully layered over
a cushion of PBS (3 ml) containing 5% sucrose, and centrifuged at 1,500 g for 10 min.
The sucrose cushion was removed and the cell pellet was suspended in 200 A1 of nuclear
counting solution (0.1 M citric acid, 0.05% naphthol blue black [Buffalo black NBR] and
1 % cetavlon, prepared as described [24]). After incubation for 30 min at room tempera-1174
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TABLE I
Stimulation ofH202 Releasefrom Human Monocytes/Macrophages by
IFN-a, -,B, and -7
Time of expo-
sure to IFNs
Days 1-4*
Days 8-11 *
* MNLs (1-2 X 106 cells/coverslip) were plated and the adherent cells cultured
as described in Materials and Methods. After 1 or 8 d, cells were exposed to the
indicated concentrations of IFNs for an additional 3 d, washed, and stimulated
with PMA to measure H202 release.
$ Mean t SEM for the number of experiments in parentheses.Milligrams pro-
tein/cell averaged fourfold higher on day 11 than on day 4. Thus, H202 release
by cells incubated with 109 U/ml rIFN-.y was almost the same on days 4 and 11
when expressed on a per cell basis.
ture, the suspension was mixed in a pipette tip and transferred to a new plastic tube.
Aliquots (7 pl) were used for the determination of the number of nuclei and the remainder
was counted in a gamma spectrometer. Specific binding of radiolabeled rIFN-y was
determined by subtracting the number of counts bound to cells in the presence of an 80-
fold excess of nonlabeled rIFN-y from the number of counts in the presence of iodinated
rIFN-'y alone. Nonspecific binding of ' 25I-rIFN-y was <20% of total binding for either
cell-bearing or cell-free coverslips. The percentage of multinucleated giant cells was <2%
by day 8, the latest day in culture at which these assays were performed. Therefore, we
used the number of nuclei per coverslip as the number of cells per coverslip. Binding
activity was expressed as ng per 106 cells.
Results
Stimulation ofH202 Releasefrom Human Macrophages by IFN-a or -,Q.
￿
With the
modified methods of cell preparation described in Materials and Methods,
macrophages resisted the dose-dependent rounding and detachment observed
previously during incubation in IFN-a or -,Q (12). This permitted a reexamination
of the ability of IFN-a or -,Q to activate mononuclear phagocytes at various stages
of maturation. We shall refer to these stages as monocytes (<_4 d culture) and
macrophages (?5 d culture).
Natural IFN-a, rIFN-aA, -aD, and -a each stimulated H202-releasing capacity
of macrophages in a dose-dependent manner at concentrations >10 U/ml (3 pM)
(Table I and detailed dose-response curves not shown). However, even at 103
U/ml (300 pM), the stimulated capacity (4 .4 ± 1 .6-fold increase over medium
IFN added
H202 released
0
at IFN concentrations (U/ml) of:
10 109
None
rIFN-,y
364 f 15 (6)$
nmol/h/mg protein$
596 t 26 (9) 699 f 21 (9)
rIFN-aA 361 ± 19 (9) 330 ± 55 (9)
rIFN-aD 357 ± 15 (6) 325 ± 37 (6)
nIFN-a 401 ± 29 (6) 330 ± 44 (6)
rIFN-# 314 ± 24 (9) 319 t 58 (9)
None 15 ± 3 (9)
rIFN--y 50 ± 8 (9) 142 ± 31 (9)
rIFN-aA 34 ± 7 (9) 82 ± 8 (9)
rIFN-aD 19 ± 1 (6) 55 ± 5 (6)
nIFN-a 16 ± 3 (6) 56 ± 3 (6)
rIFN-0 19 ± 2 (9) 73 ± 10 (9)TABLE 11
Induction ofAntitoxoplasma Activity in Human Macrophages by rIFN-y, -aA, and -fl
YOSHIDA ET AL .
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* Number of toxoplasma per 100 cells at 20 h divided by the number of toxoplasma per 100 cells
immediately after infection (time 0) .
t Beginning on day 7 of culture, macrophages were incubated with the indicated cytokines for 3 d
before being washed and challenged with toxoplasmas.The course of infection was followed in the
absence of cytokines for the next 20 h .
¢Mean f SEM for three experiments, each in triplicate,
control) was less than that (8 .4 ± 4.8-fold increase, mean ± SD for three
experiments) obtained with rIFN-y (100 U/ml, 100 pM) . When macrophages
were exposed to 10' U/ml of IFN-a or -,B for 30 min on day 8 of culture,
extensively washed to remove IFN, and then cultured in standard medium for
an additional 3 d, their peroxide-releasing capacity was as great as that of cells
exposed continuously to 10' U/ml of IFN-a or -,8 for the entire 3-d period (data
not shown) . This suggested that the stimulatory effects ofIFN-a or -,B on mature
macrophages were receptor mediated .
rIFN-aA (103 U/ml) and rIFN-,B (10' U/ml) induced detectable but modest
antitoxoplasma activity in mature macrophages . rIFN-7 (100-500 U/ml) af-
forded more pronounced macrophage activation by the same criterion . There
was a rough correlation between the increase in H202-releasing capacity and
induction of antitoxoplasma activity by these agents (Table 1I) .
In contrast, at the stage of monocytes, 103 U/ml of IFN-a or -,B failed to
increase the specific activity of H202-releasing capacity (Table I), and instead
decreased by 20-40% the amount of protein adherent to coverslips (not shown),
suggesting toxicity, as previously noted (12) .
The fivefold lower value of H202/mg protein seen in Table I for rIFN-7-
activated macrophages compared to rIFN-y-activated monocytes reflected the
approximately fourfold increase in protein/cell which accompanied maturation
of monocytes into 11-d macrophages (13) .
Suppressive Effects ofIFN-a or -,B on rIFN-y Stimulated H202-releasing Capac-
ity. For all subsequent studies, we compared monocytes (exposed to cytokines
from days 1-4 of culture) to macrophages (treated from days 8-11). We first
tested the effects of simultaneous exposure of the cells to rIFN-y plus IFN-a or
-,8. As shown in Fig . 1, cells in the two stages of differentiation gave contrasting
results . With monocytes (Fig . 1 A), IFN-a or -# had almost no effect on rIFN-7's
action, while with macrophages (Fig . 1 B), low doses ofIFN-a or -,Q (3 fm-3 pM)
blocked induction of H202-releasing capacity by far higher concentrations of
rIFN-y (10 pM) . The maximum percent inhibitions were 83 .3 ± 8.5 (mean ±
SD for seven experiments), 68.0 ± 8.0 (two experiments), 71 .0 ± 3.0 (two
IFN$ U/ml
Exp . 1
Fold increase*
Exp. 2
in toxoplasma
Exp . 3 Mean ±SD
H2021
nmol /mg/h
None 0 8.9 11 .2 5.4 8.5±2.4 7±5
rIFN-aA 10' 4.3 8.0 4.9 5.7 ± 1 .6 41 ± 30
rIFN-ft 10' 6.4 5.5 2.5 4.8± 1 .7 32 ± 10
rIFN-y 100 2.8 - - - -
rIFN-y 500 - 3.8 2.8 3.1 ± 0.5 84 ± 271176
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FIGURE 1 . Hs02 ￿release
from human tnonocytes and
macrophages exposed simul-
taneously to rIFN--y and IFN-
a or IFN-/3 . (A) Monocytes (1-
dculture) or (B) macrophages
(8-d culture) were exposed to
various concentrations of IFN-
aor -J3 with 10 U/nil of rIFN-
y. 3 d later, the cells were
washed and stimulated with
PMA to measure H202 re-
lease . Each point represents
the mean value for six experi-
ments . (/), Medium control ;
(0) rIFN--y (10 U/ml) alone ;
(O) rIFN--y (10 U/ml)+ rIFN-
aA ; (A) rIFN--y (10 U/ml) +
nIFN-a ; (x) rIFN--y (10 U/ml) + rIFN-aD; (0) rIFN--y (10 U/ml) + rIFN-/3 .
experiments), and 63 .0 ± 11 .0 (three experiments) with 0.18 pM of rIFN-aA,
0.17 pM of nIFN-a, 0.30 pM of rIFN-aD, and 0.12 pM of rIFN-(3, respectively .
At >3 pM (-10 U/ml), IFN-a or -(3 were no longer suppressive . Rather, H202-
releasing capacity appeared to equal or exceed the level obtained with rIFN--y
alone . Moreover, IFN-a or -(3 (3 fM-300 pM) could not inhibit the stimulatory
effect of 1 nM (10 s U/ml) rIFN-?' (not shown) .
Antibodies against IFN-a or -,Q inhibited the nIFN-a- or rIFN-(3-stimulated
H202-releasing capacity ofmacrophages by 78 and 85%, respectively, while these
antibodies had almost no effect (-11 .8 and 5.7% differences, respectively) on
rIFN-y's action . Moreover, antibody specific for IFN-a markedly reduced the
ability of low-dose (3 fM-3 pM, 0.01-10 U/ml) nIFN-a to inhibit the action of
rIFN-y, as well as the ability of high dose (>-3 pM) nIFN-a to augment the action
ofrIFN-y . Similar results were seen with rIFN-J3 . Thus, both the antagonist and
agonist actions of these IFN preparations appeared to be due to the IFNs
themselves and not to contaminants (data not shown) .
Time Course of IFN-a- or -(3-mediated Inhibition of rIFN-y-stimulated H202-
releasing Capacity . As a first step in determining the mechanisms of IFN-a- or
-a-mediated suppression of rIFN-y's action, time course experiments were
carried out . As shown in Fig. 2A, macrophages that were treated simultaneously
with rIFN-aA (3 fM-3 pM) and rIFN--y (10 pM) from days 8-11 of culture failed
to show the full increase in H202 release induced by rIFN--y alone. In contrast,
the addition of rIFN-aA 6 h after the addition of rIFN--y did not reduce rIFN-
y's action (Fig . 2B). When macrophages had a 6-h preexposure to rIFN-aA and
an additional 66-h exposure to rIFN-y, rIFN-y-stimulated H202 release was
suppressed (Fig . 2C). Results were similar with rIFN-0 (not shown). These results
suggested that the inhibitory effect of IFN-a or -(3 on rIFN-y-stimulated H202-
releasing capacity might involve interference with binding ofrIFN--y to its plasma
membrane receptors .
Characterization ofIFN-y Receptors .
￿
To characterize rIFN-y-Rs, we prepared
125I-rIFN-y with high specific activity and full bioactivity (see Materials and
Methods) . Mature macrophages (day 8) incubated at,4°C for 2 h in the presence
of increasing concentrations of I25I-rIFN-y yielded specific saturation isotherms,N
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FIGUxr_ 2. Time course of
IFN-a-mediated inhibition of
rIFN-y-stimulated H 202-re-
leasing capacity . (A) Macro-
phages (8-d culture) were in-
cubated with rIFN--y (10
U/ml) and various concentra-
tions of rIFN-aA. (B) Cells on
day 8 were exposed to 10
U/Inl of rIFN--y . 6 h later, var-
ious concentrations of rIFN-
aA were added . (C) Cells were
incubated on day 8 with var-
ious concentrations of rIFN-
aA for 6 h, and then 10 U/ml
of rIFN--y was added . In each
case, H202 release was meas-
ured 3 d later . Each value rep-
resents the mean ± SD of trip-
licates . (0) Medium control
(no IFNs) .
FIGURE 3 . Binding of '251-rIFN-y to human macrophages . Macrophages (2-5 X 105
cells/coverslip) were incubated with increasing concentrations of '251-rIFN-y at 4°C for 2 h.
Free radioactivity was separated from cell-bound radioactivity as described in Materials and
Methods. Each point represents the mean of duplicate determinations from one or two
experiments . (Inset) Scatchard plots of the binding data .
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illustrated for one experiment in Fig . 3 . Scatchard analysis gave biphasic curves
(Fig . 3, inset) . In three such experiments, Kd values of the two classes of rIFN-y-
Rs averaged (4.33 ± 0.33) X 10-'° M and (6 .40 ± 1 .13) X 10-s M (mean ± SD),
and binding sites per cell averaged 3,859 ± 391 and 25,110 ± 1,513, respectively .
In contrast, monocytes (day 1) and early macrophages (day 5 or 6) displayed a
single class of rIFN-y-Rs (Table III) .1178
Parameter
Kd
Sites/cell
* Our preliminary data.
$ This paper .
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TABLE III
Characteristics ofReceptorsfor rIFN--y on Human Monocytes andMacrophages
Monocytes
1 .0-1 .1 X 10-9 M*
1 .3-2.5 x 10-'°M (reference 15)
6.8 x 10-9M (reference 16)
2.0 ± 0.5 x 10-9M (reference 17)
1,324-1,850*
4,000 (reference 15)
2,400 (reference 16)
7,900 ± 400 (reference 17)
Macrophages
4.3 ± 0.3 x 10-'°M (class 1)$
6.4 ± 1 .1 X 10-9M (class 2)$
2.0 f 0.3 X 10-9M (reference 17)
^-2,000 (class 1)$
23,000 (class 2)$
7,800 ± 300 (reference 17)
FIGURE 4 .
￿
Displacement of '25I-rIFN-y from high-affinity receptors by nIFN-a . I U or 103
U/0.25 ml ofnIFN-a was added together with various concentrations of '25I-rIFN-7 . The cell-
associated radioactivity was measured aftera 2-h incubation at 4'C . Each point represents the
mean of duplicate determinations . (Inset) Scatchard plots of the binding data . (O) Without
nIFN-a ; (0) with 1 Uof nIFN-a ; (x) with 10' U of nIFN-a ; (---) predicted results if all high-
affinity binding sites for rIFN-y were blocked .
Competitive Displacement of ' 25I-rIFN-y by Recombinant and Natural IFN-a or
-/3 . In an attempt to examine whether IFN-a or -,#could interfere with binding
of rIFN-y to one or both types of IFN-y-Rs on macrophages, the effect ofnIFN-
a (I or 10' U) on `25I-rIFN-y binding was determined as a function of '25I-rIFN-
y concentration . As shown in Fig . 4 (inset), simultaneous addition ofnIFN-a with 125I-rIFN-y caused a dose-dependent reduction in the apparent number of high-
affinity receptor sites . The Kd value for high-affinity sites did not change . The
approximate number (^-2,200 sites/cell) of high affinity receptor sites for rIFN-
y, which were dissociable by nIFN-a, was obtained by calculating the number of° o
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FIGURE 5. Binding site competition be-
tween "5I-rIFN-y and unlabeled nIFN-a,
rIFN-aA, rIFN-,B, or rIFN-y. Macrophages
(^-3.5 X 105 cells/coverslip) were incubated
with 125I-rIFN-y (4 ng, -120 U) andvarious
concentrations of unlabeled IFNs for 2 h at
4°C.Data points aremeansof triplicates for
specific binding. (9) 125I-rIFN-y + rIFN-y; (0)1251-rIFN-y + nIFN-a; (A) 125I-rIFN-y +
rIFN-aA;(X) 1261-rIFN-y + rIFN-S.
binding sites in the absence of nIFN-a minus the number ofbinding sites in the
presence ofnIFN-a (10' U).
In contrast, nIFN-a was all but incapable of competing with '251-rIFN--y for
binding to the low-affinity receptors (Fig. 4). These results are in line with the
data (Fig. 1 B) regarding the effect of IFN-a or -,Q on rIFN-y-stimulated H202
release; the stimulatory effect of 10 pM rIFN-y was inhibited by simultaneous
addition of IFN-a or -,B (3 fM-300 pM), while IFN-a or -(3 (3 fM-300 pM) could
not inhibit the enhancement of H202-releasing capacity stimulated by 1 nM
rIFN-y.
The '251-rIFN-y specifically bound in the presence or absence of competitor
was plotted as a function of concentration for each competing IFN (Fig. 5). In
these experiments, 4 ng (-0.5 nM, -120 U/0.25 ml) of '251-rIFN-y was used,
sinceat this concentration, binding toitshigh-affinity receptorsreached a plateau
(Fig. 4). In a dose-dependent manner, unlabeled rIFN-y inhibited the binding
of '251-rIFN-y, and at 333 ng (^"40 nM, ^-10' U/0.25 ml), binding was almost
completely suppressed. In contrast, although nIFN-a, rIFN-aA, and rIFN-a
inhibitedthe bindingof1251-rIFN-y (4 ng, ^-0.5 nM) inadose-dependent manner,
the maximum inhibition (^-50%) was obtained with 100 pg (-20 pM) of IFN-
a or -fl. Even at 50 ng (10 nM), IFN-ca or -,B suppressed '251-rIFN-y binding by
only 40-50%. These findings are consistent with the concept that IFN-a or -a
inhibited the binding ofrIFN-y to its high-affinity sites but not to its low-affinity
sites, while rIFN-y competed with '251-rIFN-y for both high- and low-affinity
sites.
The above results indicated that IFN-a or -# interferes with binding of rIFN-
y to its high-affinity receptor on mature macrophages. This could be due to
binding of IFN-a or -,B in such a way as to sterically hinder binding of rIFN-'r,
for example, by occupying the same receptor. Alternatively, IFN-a or -0 might
exert a metabolic effect on macrophages that leads to a decrease in the number
of high-affinity rIFN-y binding sites displayed on the cell surface, such as by1180
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FIGURE 6. Effects of nIFN-a and
rIFN-y on "'I-rIFN-ybinding to human
macrophages . Macrophages (^"3 .5 x 105
cells/coverslip) were incubated with "I-
rIFN-y (4 ng) for 90 min at 4°C . The
cells were then further incubated at 4°C
in the presence (0 andA [two different
experiments]) or absence (O) of (A)
nIFN-a (50 ng)and (B) rIFN-y (300 ng).
After the time shown, the amounts of
"'I-rIFN-y specifically remainingbound
were determined . Each point represents
themean of duplicate determinations.
promoting internalization or shedding . The latter possibility seemed remote,
since the antagonism of IFN-a or -# on rIFN--y binding was manifest rapidly and
at 4°C . Nevertheless, to distinguish between a direct and indirect effect of the
competing IFNs, we tested whether they could displace 1251-rIFN-^y that had
already been bound . The binding reaction was allowed to reach equilibrium for
90 min at 4°C. 105 U of nIFN-a or 104 U of rIFN-'y were then added without
significant dilution of the incubation mixture, and the amount of 1251-rIFN-y
specifically remaining bound was determined as a function of time (Fig. 6) . In
thecase of nIFN-a, dissociation of 1251-rIFN-y from macrophages followed simple
monoexponential first order kinetics with a ty, ^-40 min and a dissociation rate
constant (k_ 1 ) of -x0.017 min-'. The association rate constant (k 1) was ^ "3.7 X 10 7
M-1 min-' at 4°C, when k_ 1 was used for the calculation, as described (25) . The
Kd (= k_ 1 /k 1) was calculated to be ^-4.7 X 10-'0 M. In contrast, dissociation of
1251-rIFN-y from macrophages after the addition of unlabeled rIFN-y showed a
deviation from linearity on a semilogarithmic plot. Approximately 50% of the
bound 1251-rIFN-y dissociated within 30 min . The rest of the binding required
>120 min for complete dissociation . Upon fitting two lines to the data, a fast
rate with a tl, of -x25 min and k'_1 of 0.028 min- ', and a slow rate with a ty, of
^-180 min and V- 1 of 0.0038, were observed . The association rate constants
(k '1 andk"1) were ^-4.3 X 106M- ' min-'and ^-5.5 X 10'M-1 min- ', respectively.
TheKd values were calculated to be ^-6.4 X 10-9 M for k'_1 and ^-7 .1 X 10-'0
M for k"_
1, respectively. TheseKd values were close to those (4.3 X 10-'0M for
the high-affinity receptor and -6.4 X 10-9 M for the low-affinity receptor)
obtained from the Scatchard analysis (Fig. 3) .
Discussion
These findings make four new points . First, in contrast to their toxic effects
on monocytes, IFN-aor -,B in high (submicromolar)concentrations enhanced the
H202-releasing capacity and antiprotozoal activity of human macrophages . Sec-
ond, the ability of low (picomolar) concentrations of rIFN-y to enhance macro-
phage H202-releasing capacity was inhibited by even lower (femtomolar) concen-
trations ofIFN-a or -fl . Third, two classes ofreceptors for rIFN-y emerged after
monocytes differentiated into macrophages in vitro. Fourth, and most surprising,
the suppressive effect of IFN-a or -,B on rIFN-y-enhanced H202-releasingYOSHIDA ET AL .
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capacity could be attributed to displacement of rIFN-y from its high-affinity
receptors by nonstimulatory binding ofIFN-a or -,8 to the same sites. Thus, the
differentiated human macrophage displays a biphasic response to IFN-a or -0 :
antagonism of IFN-y-mediated activation at low doses, and an agonist action at
higher doses .
It has been repeatedly demonstrated that IFN-y binds to a receptor different
from that for IFN-a and -a (25-27), although several groups reported some
crossreactivity between IFN-,8 and the binding site for IFN-y (28-32). The
presence of two kinds of receptors for human IFN-a (29) or -,Q (28) has been
suggested . Recently, Aiyer et al . (33) observed a curvilinear Scatchard plot for
binding of ' 21I-murine IFN-y to WEHI.3 cells. Although binding was nonsatur-
able, the authors inferred the existence oftwo classes of IFN-y receptors on this
cell line . Finbloom et al . (15) reported binding curves of '21I-human rIFN-y to
U937 and HL60 cells similar to those of Aiyer et al ., but interpreted the results
as showing negative cooperative interaction between receptors of a single class.
To our knowledge, there has heretofore been no clearcut evidence for two
classes ofreceptors for IFN-y, nor any such evidence with primary macrophages .
Table III summarizes published binding studies using rIFN-y and human
mononuclear phagocytes . Methodologic differences may account for the 52-fold
range in Kds and sixfold span in the number of binding sites reported on
monocytes . Nonetheless, four laboratories concur in describing a single class of
IFN-y-Rs at this stage in the cell's maturation ; our results for the Kd fall in the
middle of the reported range . Our limited results for early macrophages (days 4
and 6) agree closely with the one other report using cells at this stage (17) . To
our knowledge, data with more mature macrophages have not previously been
provided . Our findings suggest that a dramatic change occurs between days 6
and 8 of culture, resulting in the emergence of a new receptor, a high-affinity
site shared by all three classes ofIFNs . Competition binding experiments suggest
that the high-affinity site has a higher affinity for IFN-a and -0 than for IFN-'Y .
The results described above imply that two classes of binding sites for IFN-a
should also be detectable on mature human macrophages. Preliminary experi-
ments using radioiodinated rIFN-aA are consistent with this prediction ; binding
sites for rIFN-aA on day-11 macrophages appeared to have Kd , ^-6.7 X 10-12 M
andKd2 -3.5 X 10`°M. Moreover, binding of ' 21I-rIFNaA (0-0.5 ng/0.25 ml)
to the high-affinity sites was almost completely suppressed by addition of unla-
beled rIFN-y (200 ng/0.25 ml) (data not shown) .
When the antagonism between IFNs demonstrated in this study is described
in terms of molecules per macrophage, the remarkable efficiency of IFN-a and
-,# at blocking the binding of rIFN-y to its high-affinity receptors becomes
apparent . 50% inhibition of binding of rIFN-y to ^-2,000 high-affinity sites per
macrophage required an input of -x900 molecules per cell (^-10 pg per coverslip)
of IFN-a or -# (Fig . 5) . Given that one term in these calculations is the specific
activity of the IFN preparations, which has an accuracy of a factor of 2, it can
be estimated that 50-100% of the added IFN-a or -# was bound, while in the
absence of IFN-a or -0, only -0.8% of input rIFN-y was bound under the same
conditions . Therefore, the high-affinity sites on mature human macrophages
appear to have an ^-100-fold higher affinity for IFN-a or -,Q than for rIFN--y .1182
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Yet, binding of IFN-a or -,B to these sites elicited no response by the criteria used
in this study. Of course, such binding may have other biologic effects. The basis
of the crossreactive binding may lie in the structural similarities between IFN-a,
-,Q, and -y described by DeGrado et al. (34).
The capacity oflow-affinity IFN-a and -,0 Rs to signal an agonist response, and
the emergence of high-affinity binding sites for IFN-a or -,0 mediating an
antagonist response to simultaneously added IFN-y, should be considered in
conjunction with the possible production of small amounts of IFN-a or -,0 by
unstimulated macrophages (35, 36) and large amounts by stimulated cells (37).
Thus, depending on how much IFN-a or -a they make, macrophages could
either interfere with or promote their own activation. For example, there is a
gradual rightward shift in the rIFN-y dose-response curve for induction of
H202-releasing capacity as macrophages progress in culture to day 8; this shift
can be forestalled by addition of neutralizing antibody for IFN-a (data not
shown).
Speculation on the possible physiologic import ofthese findings must keep in
mind the resistance of monocytes and young macrophages to the IFN-'r-antag-
onizing action oflow-dose IFN-a and -#, the ability of moderate concentrations
of rIFN-y (--1O' U/ml, ^-1 nM) to overcome this antagonism, and the agonist
rather than antagonist effects ofhigher concentrations of IFN-a or -/3. Thus, the
phenomenon of antagonism is unlikely to impinge on immigrant monocytes or
inflammatory macrophages (which are young cells), or on resident tissue macro-
phages at the site of an immune response (where the concentration of IFNs is
likely to be high). However, trace amounts of IFN-a or -# produced by stromal
cells, parenchymal cells, and resident macrophages, perhaps constitutively, could
be expected to damp the response of mature tissue macrophages to 1-10 U/ml
IFN-y. This may serve to prevent oxidant- or protease-mediated tissue damage
by resident macrophages when low levels of IFN-y circulate or diffuse into
uninvolved tissues from sites of an immune response. Thus, the interaction of
cytokines described here may function in the regional containment of macro-
phage activation .
Summary
H202-releasing capacity and limited antitoxoplasma activity could be induced
in human macrophages (derived from monocytes cultured ?5 d) but not in
monocytes themselves (cells cultured <_4 d) by a further 3-dincubation with pure
natural or rIFN-a or -0. More than 3 pM (10 U/ml) ofthese IFNs was required,
with greatest effects at ^-300pM (10' U/ml). At 300 pM, H202-releasing capacity
was enhanced 4.4 ± 1 .6-fold over medium control (mean ± SD for natural IFN-
a, rIFN-aA, rIFN-aD, and rIFN-R) compared to an 8.4 ± 4.8-fold increase with
rIFN-y (100 pM, 100 U/ml) in the same experiments. Unexpectedly, low
concentrations of IFN-a or -/3 (3 fM-300 pM) blocked induction of H202-
releasing capacity by rIFN-y (10 pM), with a 50% inhibitory dose of -80 fM.
However, IFN-a or -(3 (3 fM-300 pM) could not inhibit the effect of higher
concentrations of rIFN-y (1 nM). In contrast to results with monocytes or young
macrophages, Scatchard plots of binding of '25I-rIFN-y to mature macrophages
(day 8 ofculture) indicated two classes ofbinding sites: ^"2,000 high-affinity sitesYOSHIDA ET AL.
￿
1183
(Kd ^-0.43 nM) and ^-23,000 low-affinity sites (Kd ^-6 .4 nM) per cell. Binding of
1251-rIFN-y to the high- but not the low-affinity sites was blocked by simultane-
ously added IFN-a or -,B, with a 50% inhibitory dose of -2 U/0.25 ml (~2 pM),
or reversed by subsequently added IFN-a or -,l.
Thus, differentiation of human mononuclear phagocytes in vitro is accom-
panied by the emergence of (a) an agonist response to submicromolar concentra-
tions of IFN-a or -,B, (b) antagonism of the effect of picomolar IFN-y by
femtomolar IFN-a or -0, (c) two classes of IFN-y-Rs, and (d) nonstimulatory
binding of IFN-a or -,Q to the high- but not the low-affinity IFN-y-Rs, with higher
affinity than rIFN-y itself. We speculate that traces of IFN-a or -,B derived from
stromal cells, parenchymal cells, or resident macrophages may dampen the
activation of mature tissue macrophages by the small amounts of IFN-y that
diffuse from inflammatory sites into normal tissues. Such a mechanism could
constrain the potentially destructive phenomenon of macrophage activation to
areas where monocytes have recently immigrated and/or the concentration of
IFNs is high .
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